The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
MeSH Review

Economics, Pharmaceutical

Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Economics, Pharmaceutical


High impact information on Economics, Pharmaceutical


Biological context of Economics, Pharmaceutical


Associations of Economics, Pharmaceutical with chemical compounds


Gene context of Economics, Pharmaceutical


Analytical, diagnostic and therapeutic context of Economics, Pharmaceutical


  1. Sedation in the intensive care unit. Young, C., Knudsen, N., Hilton, A., Reves, J.G. Crit. Care Med. (2000) [Pubmed]
  2. Cost-effectiveness analysis for onychomycosis therapy in Canada from a government perspective. Einarson, T.R., Arikian, S.R., Shear, N.H. Br. J. Dermatol. (1994) [Pubmed]
  3. Neutropenia and neoplasia: an overview of the pharmacoeconomics of sargramostim in cancer therapy. Desch, C.E., Ozer, H. Clinical therapeutics. (1997) [Pubmed]
  4. Enoxaparin: a pharmacoeconomic review of its use in the prevention and treatment of venous thromboembolism and in acute coronary syndromes. Bergqvist, D. PharmacoEconomics. (2002) [Pubmed]
  5. Health economics: implications for novel antirheumatic therapies. Kavanaugh, A. Ann. Rheum. Dis. (2005) [Pubmed]
  6. Recombinant human erythropoietin in oncology: current status and further developments. Engert, A. Ann. Oncol. (2005) [Pubmed]
  7. Patient management issues in metastatic bone disease. Cameron, D. Semin. Oncol. (2004) [Pubmed]
  8. The safety, efficacy, and pharmacoeconomics of low-dose alteplase compared with urokinase for catheter-directed thrombolysis of arterial and venous occlusions. Sugimoto, K., Hofmann, L.V., Razavi, M.K., Kee, S.T., Sze, D.Y., Dake, M.D., Semba, C.P. J. Vasc. Surg. (2003) [Pubmed]
  9. Liposomal amphotericin B versus conventional amphotericin B in the empirical treatment of persistently febrile neutropenic patients. Cagnoni, P.J. J. Antimicrob. Chemother. (2002) [Pubmed]
  10. Clinical and medicoeconomic impact of the cyclosporine-diltiazem interaction in renal transplant recipients. Smith, C.L., Hampton, E.M., Pederson, J.A., Pennington, L.R., Bourne, D.W. Pharmacotherapy (1994) [Pubmed]
  11. Further profiles of granisetron (Kytril): effect on quality of life and pharmacoeconomics. Eisenberg, P.D. Semin. Oncol. (1994) [Pubmed]
  12. Pharmacoeconomics of angiotensin converting enzyme inhibitors in heart failure. Szucs, T.D. Am. J. Hypertens. (1997) [Pubmed]
  13. A retrospective assessment of safety, efficacy, and pharmacoeconomics of generic azathioprine in heart-transplant recipients. Haroldson, J.A., Somerville, K.T., Carlson, S., Hanson, J., Emery, R.W., Lake, K.D. J. Heart Lung Transplant. (2001) [Pubmed]
  14. Selective serotonin reuptake inhibitors in the treatment of affective disorders--III. Tolerability, safety and pharmacoeconomics. Goldstein, B.J., Goodnick, P.J. J. Psychopharmacol. (Oxford) (1998) [Pubmed]
  15. Pharmacoeconomics of piperacillin/tazobactam and imipenem/cilastatin in the treatment of patients with intra-abdominal infections. Jhee, S.S., Gill, M.A., Yellin, A.E., Berne, T.V., Heseltine, P.N., Appleman, M.D. Clinical therapeutics. (1995) [Pubmed]
  16. The pharmacoeconomics of peri-operative beta-blocker therapy. Biccard, B.M., Sear, J.W., Foëx, P. Anaesthesia. (2006) [Pubmed]
  17. Use of pharmacoeconomics in prescribing research. Part 4: is cost-utility analysis a useful tool? Brinsmead, R., Hill, S. Journal of clinical pharmacy and therapeutics. (2003) [Pubmed]
  18. Overview of the lenograstim pharmacoeconomics programme. Oster, G., Menzin, J., Richard, D., Cour-Chabernaud, V. PharmacoEconomics. (1994) [Pubmed]
  19. The burden and pharmacoeconomics of epilepsy in India. Kuruvilla, A. Seizure : the journal of the British Epilepsy Association. (1999) [Pubmed]
  20. Pharmacoeconomic impact of non-compliance with statins. Peterson, A.M., McGhan, W.F. PharmacoEconomics. (2005) [Pubmed]
  21. Mifepristone. DeHart, R.M., Morehead, M.S. The Annals of pharmacotherapy. (2001) [Pubmed]
WikiGenes - Universities